Top

Archives of Gynecology and Obstetrics

Published in:

01-08-2011 | Gynecologic Oncology

E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis

Authors: Darius Dian, Ansgar Brüning, Ioannis Mylonas

Published in: Archives of Gynecology and Obstetrics | Issue 2/2011

Abstract

Introduction

Ovarian cancer is a gynecologic cancer with a high mortality rate, demonstrating the need for effective and reliable tumor markers during the staging and treatment processes.

Methods

Expression of E-cadherin was immunohistochemically analyzed in 100 ovarian cancer tissue samples.

Results

A significant association of E-cadherin expression with histological grading (p = 0.001) and surgical stage (p = 0.020) could be demonstrated. However, the staining intensity of E-cadherin was not significantly associated with progression-free, cause-specific survival or overall survival in serous ovarian carcinomas.

Conclusion

The E-cadherin expression was associated with FIGO surgical staging and histological differentiation in serious ovarian carcinomas, suggesting a substantial role in the carcinogenesis of serous ovarian carcinomas. However, although patients with a strong E-cadherin staining intensity had a better prognosis, no statistical significant differences could be observed. Therefore, E-cadherin might not be a useful prognostic tumor marker in serous ovarian carcinomas.

Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I (2006) Ovarian cancer. Crit Rev Oncol Hematol 60(2):159–179. doi:10.1016/j.critrevonc.2006.03.004 PubMedCrossRef

International Agency for Research on Cancer I. Descriptive Epidemiology Group of IARC (2008) GLOBOCAN 2002 database. http://www-dep.iarc.fr/2

National Cancer Institute (2006) SEER Surveillance, Epidemiology and End Results: SEER Cancer Statistics Review, 1975–2003. http://seer.cancer.gov/csr/1975_2003/3

Abaid LN, Goldstein BH, Lopez KL, Micha JP, Brown JV, 3rd, Rettenmaier MA, Markman M (2010) The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy. Arch Gynecol Obstet. doi:10.1007/s00404-010-1571-5

Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S (2003) Carcinoma of the ovary. Int J Gynaecol Obstet 83(Suppl):1135–1166

Lenhard SM, Bufe A, Kumper C, Stieber P, Mayr D, Hertlein L, Kirschenhofer A, Friese K, Burges A (2009) Relapse and survival in early-stage ovarian cancer. Arch Gynecol Obstet 280(1):71–77. doi:10.1007/s00404-008-0877-z PubMedCrossRef

Munstedt K, Hackethal A, Eskef K, Hrgovic I, Franke FE (2009) Prognostic relevance of granulocyte colony-stimulating factor in ovarian carcinomas. Arch Gynecol Obstet. doi:10.1007/s00404-009-1319-2

Miyazawa M, Yasuda M, Fujita M, Hirasawa T, Kajiwara H, Hirabayashi K, Ogane N, Shimizu M, Asanuma H, Murakami M, Takekoshi S, Mikami M, Osamura RY (2009) Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Arch Gynecol Obstet 279(6):789–796. doi:10.1007/s00404-008-0816-z PubMedCrossRef

Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009) The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet 279(1):53–56. doi:10.1007/s00404-008-0673-9 PubMedCrossRef

10.

Hogdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ, Hogdall CK (2007) CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients From The Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol 104(3):508–515PubMedCrossRef

11.

Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X, Jiang SW (2009) HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 9(6):555–566. doi:10.1586/erm.09.39 PubMedCrossRef

12.

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK (2009) The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma : a Gynecologic Oncology Group study. Cancer. doi:10.1002/cncr.24084

13.

Birchmeier W, Hulsken J, Behrens J ((1995)) E-cadherin as an invasion suppressor. Ciba Found Symp 189:124–136 (discussion 136–141, 174–126)

14.

Birchmeier W, Behrens J (1994) Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1198(1):11–26PubMed

15.

Brinck U, Jacobs S, Neuss M, Tory K, Rath W, Kulle B, Fuzesi L (2004) Diffuse growth pattern affects E-cadherin expression in invasive breast cancer. Anticancer Res 24(4):2237–2242PubMed

16.

Berx G, Van Roy F (2001) The E-cadherin–catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3(5):289–293PubMedCrossRef

17.

Yalta T, Atay L, Atalay F, Caydere M, Gonultas M, Ustun H (2009) E-cadherin expression in endometrial malignancies: comparison between endometrioid and non-endometrioid carcinomas. J Int Med Res 37(1):163–168PubMed

18.

Scholten AN, Aliredjo R, Creutzberg CL, Smit VT (2006) Combined E-cadherin, alpha-catenin, and beta-catenin expression is a favorable prognostic factor in endometrial carcinoma. Int J Gynecol Cancer 16(3):1379–1385PubMedCrossRef

19.

Stawerski P, Wagrowska-Danilewicz M, Stasikowska O, Gottwald L, Danilewicz M (2008) Immunoexpression of beta-catenin–E-cadherin complex in primary serous ovarian tumors. Pol J Pathol 59(1):27–32PubMed

20.

Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Hofler H, Becker KF (2008) The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer 98(2):489–495. doi:6604115[pii]10.1038/sj.bjc.6604115 PubMedCrossRef

21.

Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS (2004) Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol 15(10):1535–1542. doi:10.1093/annonc/mdh38715/10/1535 PubMedCrossRef

22.

Imai T, Horiuchi A, Shiozawa T, Osada R, Kikuchi N, Ohira S, Oka K, Konishi I (2004) Elevated expression of E-cadherin and alpha-, beta-, and gamma-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 35(12):1469–1476PubMedCrossRef

23.

Marques FR, Fonsechi-Carvasan GA, De Angelo Andrade LA, Bottcher-Luiz F (2004) Immunohistochemical patterns for alpha- and beta-catenin, E- and N-cadherin expression in ovarian epithelial tumors. Gynecol Oncol 94(1):16–24PubMedCrossRef

24.

Voutilainen KA, Anttila MA, Sillanpaa SM, Ropponen KM, Saarikoski SV, Juhola MT, Kosma VM (2006) Prognostic significance of E-cadherin–catenin complex in epithelial ovarian cancer. J Clin Pathol 59:460–467PubMedCrossRef

25.

Yuecheng Y, Hongmei L, Xiaoyan X (2006) Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis 23(1):65–74. doi:10.1007/s10585-006-9020-3 PubMedCrossRef

26.

Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Ferreira VM, Lopes CS (2004) Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Hum Pathol 35(6):663–669PubMedCrossRef

27.

Burges A, Bruning A, Dannenmann C, Blankenstein T, Jeschke U, Shabani N, Friese K, Mylonas I (2010) Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 281(3):511–517. doi:10.1007/s00404-009-1185-y PubMedCrossRef

28.

Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Bruning A (2008) The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther 7(9):1460–1467PubMedCrossRef

29.

Anonymous (1989) FIGO stages (announcements)—revision. Gynecol Oncol 35 125–127

30.

Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K (2009) Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 45(7):1304–1314. doi:10.1016/j.ejca.2009.01.008 PubMedCrossRef

31.

Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I (2007) Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 43(16):2434–2444. doi:10.1016/j.ejca.2007.08.014 PubMedCrossRef

32.

Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef

33.

Perez-Moreno M, Jamora C, Fuchs E (2003) Sticky business: orchestrating cellular signals at adherens junctions. Cell 112:535–548PubMedCrossRef

34.

Darai E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, Potet F (1997) Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol 28:922–928PubMedCrossRef

35.

Fujioka T, Takebayashi Y, Kihana T, Kusanagi Y, Hamada K, Ochi H, Uchida T, Fukumoto M, Ito M (2001) Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma. Oncol Rep 8(2):249–255PubMed

36.

Patel IS, Madan P, Getsios S, Bertrand MA, MacCalman CD (2003) Cadherin switching in ovarian cancer progression. Int J Cancer 106(2):172–177. doi:10.1002/ijc.11086 PubMedCrossRef

37.

Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brannstrom M, Janson PO, Enerback S, Hedin L (1997) E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 74(3):275–280. doi:10.1002/(SICI)1097-0215(19970620)74:3<275:AID-IJC7>3.0.CO;2-W PubMedCrossRef

38.

Behrens J, Mareel MM, Van Roy FM, Birchmeier W (1989) Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 108(6):2435–2447PubMedCrossRef

39.

Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D, Birchmeier W (1991) E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113(1):173–185PubMedCrossRef

40.

Veatch AL, Carson LF, Ramakrishnan S (1994) Differential expression of the cell-cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int J Cancer 58(3):393–399PubMedCrossRef

41.

Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S, Somasiri A, Roskelley CD (1999) E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 96(11):6249–6254PubMedCrossRef

Title: E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis
Authors: Darius Dian
Ansgar Brüning
Ioannis Mylonas
Publication date: 01-08-2011
Publisher: Springer-Verlag
Published in: Archives of Gynecology and Obstetrics / Issue 2/2011
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-010-1657-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2011

Fertility preservation in women—a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT

Abdominal, vaginal and total laparoscopic hysterectomy: perioperative morbidity

Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors

Laparoscopic-assisted vaginal hysterectomy with and without laparoscopic transsection of the uterine artery: an analysis of 1,255 cases

Influence of pregnancy and smoking on brachial artery flow-mediated dilation values and time until maximum response

B cell acute lymphocytic leukemia in pregnancy